Gene Therapy Products

Gene Therapy Products Market Outlook

As of 2023, the global gene therapy products market is valued at approximately USD 6 billion and is projected to reach USD 24 billion by 2035, growing at a remarkable compound annual growth rate (CAGR) of 12.5% during the forecast period. This substantial growth can be attributed to several factors including the rising prevalence of genetic disorders and chronic diseases, advancements in biotechnology, and increased investments in research and development activities. Furthermore, the growing acceptance and approval of innovative gene therapies by regulatory bodies such as the FDA are propelling market expansion. The surge in personalized medicine and targeted gene therapies, coupled with improved healthcare infrastructure, is also contributing to the positive trajectory of this market.

Growth Factor of the Market

The gene therapy products market is primarily driven by an increasing incidence of genetic disorders and the need for effective treatment options. As healthcare providers and researchers continue to explore the potential of gene therapy as a means to correct genetic defects, the market is witnessing a surge in innovative product launches. Moreover, advancements in technology, particularly in gene editing tools like CRISPR and other gene delivery systems, have improved the efficacy and safety of gene therapies, attracting significant investment from pharmaceutical companies. The global push towards personalized medicine, which tailors treatment to individual genetic profiles, is reinforcing the demand for gene therapy solutions. Regulatory approvals of groundbreaking therapies, combined with strategic partnerships among biopharmaceutical companies, are further fueling market growth. Collectively, these factors indicate a promising landscape for gene therapy products in the years ahead.

Key Highlights of the Market

• The gene therapy products market is expected to grow at a CAGR of 12.5% from 2025 to 2035.
• North America dominates the market, accounting for over 45% of the global share.
• Gene editing techniques such as CRISPR are revolutionizing treatment options.
• Oncology applications make up the largest segment within the market.
• Viral vectors are the most utilized ingredient type for gene therapy products.

By Product Type

Gene Editing:

Gene editing is a transformative approach that allows for the precise modification of an organism's genetic material. This segment includes technologies such as CRISPR-Cas9, TALENs, and ZFNs, which have gained significant traction in research and clinical settings. The ability to make targeted changes to genes enables researchers to correct mutations that cause diseases, thus opening new avenues for treatment. As gene editing technology continues to evolve, its applications in various fields, including oncology, genetic disorders, and agricultural biotechnology, are expanding rapidly. The increasing number of clinical trials and successful outcomes from gene editing therapies is expected to drive substantial growth in this segment of the market over the coming years.

Gene Silencing:

Gene silencing involves the downregulation of gene expression, which can be particularly useful in the treatment of diseases caused by overexpression of certain genes. Techniques such as RNA interference (RNAi) are employed to silence unwanted gene activity effectively. This method holds great promise for treating various conditions, including cancers and genetic disorders. The growing body of research supporting gene silencing as a viable therapeutic option, along with advancements in delivery mechanisms that enhance the stability and efficacy of RNAi, is expected to support the growth of this segment. Moreover, successful clinical applications are driving increased interest and investment in developing new gene-silencing agents.

Gene Transfer:

Gene transfer is a crucial method in gene therapy that involves delivering therapeutic genetic material into specific cells or tissues. This can be achieved through several mechanisms, including viral vector delivery and non-viral methods. Viral vectors, such as lentiviruses and adenoviruses, are among the most common vehicles for gene transfer due to their high efficiency in transducing target cells. The demand for effective gene transfer technologies is escalating as researchers seek to develop innovative therapies for both inherited and acquired diseases. The growth of gene transfer techniques is driven by the increasing number of clinical applications and the development of novel vector systems that can improve transfection efficiency and reduce immunogenicity.

Gene Regulation:

Gene regulation encompasses techniques that modulate gene expression to achieve therapeutic effects. This includes strategies such as transcriptional regulators and epigenetic modifications that can silence or activate specific genes. As research uncovers the complex roles of gene regulation in various diseases, the potential for targeted therapies that can fine-tune gene expression is becoming more apparent. This segment is bolstered by advancements in technologies that allow for precise control over gene activity, thereby enhancing the effectiveness of gene therapy approaches. The growing interest in understanding gene regulation mechanisms is expected to contribute to innovation and expansion in this market segment.

Others:

This category includes any additional gene therapy techniques not classified under the primary types. Innovations and experimental approaches in gene therapy are continually being developed, which may lead to new products and market entrants. Such developments could involve next-generation sequencing technologies and novel delivery systems that enhance the therapeutic potential of gene therapies. The continuous evolution of the gene therapy landscape indicates that the "Others" segment will likely see growth driven by emerging research and product development aimed at addressing unmet clinical needs.

By Application

Oncology:

Oncology is one of the primary applications of gene therapy, as cancer is often driven by genetic mutations and aberrations in gene expression. Gene therapies designed for cancer treatment aim to either correct these genetic errors or induce cancer cell death. The use of gene editing techniques to target oncogenes or tumor suppressor genes is gaining prominence, and many clinical trials are currently exploring these options. The increasing incidence of various cancers globally is propelling the demand for effective therapeutic solutions, making oncology a significant growth driver within the gene therapy market.

Genetic Disorders:

Genetic disorders arise from abnormalities in an individual's DNA, which can often be addressed through gene therapy. The application of gene therapy in this segment focuses on correcting or replacing defective genes responsible for inherited conditions. Advances in gene editing technology, particularly CRISPR and other gene delivery systems, have shown promise in treating genetic disorders such as cystic fibrosis, hemophilia, and sickle cell disease. As awareness and diagnosis of genetic conditions grow, so does the potential for gene therapy solutions to provide effective treatments for these disorders, driving market growth in this application area.

Neurological Disorders:

Neurological disorders often have a genetic component, making them a prime target for gene therapy interventions. Conditions such as spinal muscular atrophy and certain types of inherited neuropathies can potentially be treated by introducing corrective genes or silencing disease-causing mutations. The ability of gene therapy to address the root cause of neurological conditions presents a significant opportunity for transforming treatment paradigms. Research is ongoing, and several clinical trials are in progress to evaluate the safety and efficacy of gene therapies for neurological disorders, indicating strong growth potential in this application segment.

Cardiovascular Diseases:

Cardiovascular diseases, including heart attacks, heart failure, and congenital heart defects, represent a substantial burden on global health systems. Gene therapy can play a transformative role in treating these conditions by promoting regeneration and repair of cardiac tissues or modulating risk factors. Innovative approaches utilizing gene delivery techniques are being explored to enhance heart function and improve outcomes for patients with cardiovascular diseases. As advancements in gene therapy technologies continue to emerge, this segment is expected to experience significant growth in the coming years, driven by increasing investments and research efforts targeted towards cardiovascular applications.

Others:

In addition to the major applications outlined, there exist a variety of other diseases and conditions that may benefit from gene therapy interventions. This includes autoimmune diseases, metabolic disorders, and infectious diseases, among others. The versatility of gene therapy techniques allows for their application across a broad spectrum of medical fields, providing numerous opportunities for innovation. As researchers continue to explore novel applications and mechanisms, this segment of the gene therapy market is likely to expand, driven by breakthroughs in scientific research that pave the way for new therapeutic interventions.

By Distribution Channel

Hospitals:

Hospitals are a primary distribution channel for gene therapy products, serving as the frontlines for patient care and treatment administration. Many gene therapies are administered in clinical settings, where healthcare professionals can monitor patients for efficacy and potential adverse events. As gene therapy becomes more prevalent, hospitals are increasingly equipped with the necessary technology and expertise to deliver these advanced treatments. The growing demand for specialized treatment options in hospitals indicates a robust market presence for gene therapy products, supported by ongoing advancements in medical technologies and healthcare infrastructure.

Specialty Clinics:

Specialty clinics are focusing on specific areas of gene therapy, such as oncology and genetic disorders, providing targeted services to patients requiring these advanced treatments. These clinics often have specialized expertise and resources to handle complex gene therapies, ensuring optimal patient outcomes. The rise of personalized medicine is contributing to the growth of specialty clinics, as patients seek tailored treatment approaches that can be effectively managed by trained professionals. As the gene therapy landscape continues to evolve, specialty clinics are expected to play an increasingly important role in patient care, making them a crucial distribution channel for gene therapy products.

Research Institutes:

Research institutes are pivotal in the development of new gene therapies and play a crucial role in conducting clinical trials to test the safety and efficacy of these products. These institutions are often at the forefront of scientific discovery, driving innovation in gene therapy through rigorous research and collaborations with biopharmaceutical companies. As gene therapy progresses from the research phases to commercial applications, the insights gained from research institutes will significantly influence the types of products entering the market. Consequently, the involvement of research institutes stands as a vital distribution channel that facilitates the progression of gene therapy from bench to bedside.

Online Pharmacies:

Online pharmacies represent an emerging distribution channel for gene therapy products, especially as digital health solutions gain traction. The increasing acceptance of telehealth and e-commerce in the healthcare space offers patients convenience and accessibility in acquiring therapeutic products. While the distribution of gene therapies through online pharmacies may still face regulatory challenges, the potential for streamlined access to treatments is significant. The growing trend towards digitization in healthcare indicates that online pharmacies will likely play an important role in distributing gene therapies, especially as more products gain regulatory approval and demand continues to rise.

Others:

The "Others" category in the distribution channel segment encompasses various emerging platforms and alternative avenues through which gene therapy products may be delivered to patients. This includes collaborations with biotech companies, direct-to-patient models, and participation in clinical trial networks that allow for controlled access to novel therapies. These alternative distribution channels are crucial for enhancing patient access and ensuring that innovative gene therapies reach those in need. As the gene therapy landscape expands, these emerging channels will likely gain prominence, contributing to the overall growth and accessibility of gene therapy products.

By Ingredient Type

Viral Vectors:

Viral vectors are among the most widely used ingredients in gene therapy due to their efficiency in delivering genetic material into target cells. These vectors are derived from viruses that have been modified to ensure safety while retaining their ability to infect cells. Common types of viral vectors include adenoviruses, lentiviruses, and adeno-associated viruses (AAVs). The versatility of viral vectors makes them suitable for various applications, including cancer therapy and treatment for genetic disorders. Given their proven efficacy and safety profiles, viral vectors are expected to dominate the gene therapy ingredient market, driving significant growth within this segment.

Non-viral Vectors:

Non-viral vectors serve as an alternative to viral vectors for gene delivery in gene therapy. These methods include liposomes, nanoparticles, and electroporation, which have gained interest due to their safety and ease of manufacturing. Non-viral vectors offer the potential for more control over the delivery of genetic material and can be particularly beneficial in applications where viral vectors may pose risks. The demand for non-viral vectors is increasing, as researchers explore their potential in diverse therapeutic areas, including oncology and genetic disorders, suggesting a growing market presence for this ingredient type.

Plasmid DNA:

Plasmid DNA is a crucial component in gene therapy, serving as a vehicle for delivering therapeutic genes into cells. Plasmids are small circular DNA molecules that can be easily manipulated in the laboratory to incorporate therapeutic genes. Their ability to replicate independently within a host cell allows for sustained expression of the delivered gene, making plasmid DNA a valuable tool in various gene therapy applications. The increasing use of plasmid DNA in research and clinical settings is propelling growth in this ingredient category, particularly as researchers continue to explore innovative gene delivery strategies and therapeutic applications.

Antisense Oligonucleotides:

Antisense oligonucleotides (ASOs) are short, synthetic strands of nucleotides designed to bind to specific messenger RNA (mRNA) and inhibit gene expression. This approach allows for the targeted silencing of genes associated with diseases, making ASOs a powerful tool in gene therapy. The ability to design ASOs that target specific genes has opened new avenues for treating various conditions, including genetic disorders and certain cancers. As the understanding of gene regulation and expression deepens, the market for antisense oligonucleotides is expected to witness significant growth, reinforcing their importance within the gene therapy ingredients landscape.

Others:

The "Others" category encompasses any additional ingredients or delivery systems utilized in gene therapy that do not fit into the primary categories. This may include novel delivery mechanisms, such as exosomes and peptides that facilitate the transport of genetic material into target cells. As research in the field of gene therapy continues to advance, new ingredients and delivery systems are likely to emerge, further enriching the market landscape. The dynamic nature of this segment highlights the continual evolution of gene therapy ingredients, promising ongoing opportunities for innovation and development.

By Region

The regional analysis of the gene therapy products market reveals significant variations in market size and growth potential across different geographical areas. North America currently leads the market, accounting for over 45% of the global share, driven by high healthcare expenditure, advanced research infrastructure, and a robust regulatory framework that supports the rapid development and approval of gene therapies. The region's strong focus on biotechnology and pharmaceuticals, coupled with the presence of key industry players, has positioned North America as a dominant force in the gene therapy landscape. The CAGR for this region is projected to remain strong due to ongoing research initiatives and increasing investments in gene therapy by both public and private sectors.

In Europe, the gene therapy products market is also experiencing considerable growth, with an estimated market share of approximately 30%. The region benefits from a well-established healthcare system and a growing number of clinical trials assessing gene therapies for various diseases. As European regulatory agencies, such as the European Medicines Agency (EMA), continue to support innovative therapies, the market is expected to expand. The Asia Pacific region is emerging as a significant player in the gene therapy products market, largely fueled by increasing investments in healthcare infrastructure and rising incidences of genetic disorders. The CAGR in Asia Pacific is projected to be around 15%, reflecting the region's growing importance in the global gene therapy landscape. Latin America and the Middle East & Africa represent smaller market shares but are also seeing a rise in research activities and partnerships aimed at advancing gene therapy solutions.

Opportunities

The gene therapy products market presents numerous opportunities for growth as the scientific community continues to explore the vast potential of gene therapy. The escalating prevalence of genetic disorders and chronic diseases creates an urgent need for innovative treatment options that can address the root causes of these conditions. As more successful clinical trials emerge, they will pave the way for new therapies to reach the market, opening up opportunities for companies dedicated to gene therapy research and development. Moreover, advancements in technology, particularly gene editing tools and vector design, are enhancing the efficacy and safety of gene therapies, encouraging investment in this space. As the healthcare industry transitions towards personalized medicine, gene therapies that can be tailored to individual patient profiles will become increasingly sought after, creating a lucrative market for developers and investors alike.

Furthermore, strategic partnerships between biopharmaceutical companies, research institutions, and healthcare providers are fostering collaboration and innovation in the gene therapy sector. These partnerships can accelerate the development and commercialization of new therapies, providing a competitive edge for companies involved in gene therapy. Additionally, regulatory bodies across the globe are becoming more supportive of innovative therapies, expediting the approval processes for gene treatments. This regulatory support will facilitate quicker access to therapies for patients, further driving growth in the gene therapy products market. Overall, the confluence of increasing demand, technological advancements, and collaborative efforts among industry stakeholders presents robust opportunities for growth in the coming years.

Threats

While the gene therapy products market holds immense promise, it is not without its challenges and threats. One of the primary concerns is the high cost associated with developing and producing gene therapies, which may limit accessibility for patients and healthcare systems, especially in low- to middle-income countries. The complex nature of gene therapies often leads to lengthy development timelines and substantial financial investments, raising questions about the sustainability of business models in this sector. Additionally, the regulatory environment is evolving, and potential changes in regulations could pose challenges for gene therapy developers. Companies must remain vigilant and adaptable to navigate these regulatory landscapes effectively, as any delays in approvals could hinder market entry for new products.

Moreover, ethical concerns surrounding gene therapy, particularly regarding genetic modifications, can generate public apprehension. The potential for misuse of gene therapy technologies, such as designer babies or unintended consequences of genetic alterations, could lead to increased scrutiny from regulatory bodies and advocacy groups. This public sentiment may impact investment and research efforts in the field. Furthermore, competition from alternative treatment modalities, such as small molecule drugs and traditional therapies, poses a significant challenge. As the gene therapy landscape becomes more crowded, companies will need to differentiate their products and demonstrate clear advantages over existing therapies to succeed in this evolving market.

Competitor Outlook

• Novartis
• Gilead Sciences
• Bluebird Bio
• Spark Therapeutics
• CRISPR Therapeutics
• Amgen
• Biogen
• Regeneron Pharmaceuticals
• AstraZeneca
• Roche
• AbbVie
• Sanofi
• Vertex Pharmaceuticals
• Intellia Therapeutics
• Catalent

The competitive landscape within the gene therapy products market is characterized by numerous players actively striving for innovation and market leadership. Major biopharmaceutical companies such as Novartis, Gilead Sciences, and Bluebird Bio are at the forefront, with expansive research and development capabilities that enable them to explore groundbreaking therapies. These companies engage in intensive clinical trials to evaluate the safety and efficacy of their gene therapies, often showcasing promising results that contribute to their competitive edge. Additionally, many of these firms are pursuing strategic collaborations with academic institutions and research organizations to enhance their product pipelines, thereby positioning themselves for future success in the gene therapy space.

Emerging companies like CRISPR Therapeutics and Intellia Therapeutics are gaining traction by focusing on innovative gene editing technologies. Their emphasis on CRISPR gene editing tools places them in a unique position to capitalize on the growing interest in gene therapies that yield precise genetic modifications. The competitive landscape is further bolstered by companies such as Spark Therapeutics and Amgen, which are dedicated to developing viral vector-based therapies for various conditions. These firms are leveraging their expertise in vector design and gene delivery systems to offer advanced treatment options for genetic disorders and cancers.

As the gene therapy market continues to evolve, collaboration and acquisition strategies will play a crucial role in determining success. Leading companies are increasingly seeking to bolster their portfolios through mergers and acquisitions, allowing them to access novel technologies and expand their market reach. Additionally, the competitive pressure to innovate and improve therapeutic outcomes is driving investments in research and development across the board. As a result, the gene therapy products market is expected to remain dynamic, with a range of competitors striving to establish themselves as leaders in this rapidly advancing field.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Roche
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Biogen
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Catalent
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Novartis
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AstraZeneca
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Bluebird Bio
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Spark Therapeutics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 CRISPR Therapeutics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Intellia Therapeutics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Vertex Pharmaceuticals
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Regeneron Pharmaceuticals
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Gene Therapy Products Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Genetic Disorders
    • 6.1.3 Neurological Disorders
    • 6.1.4 Cardiovascular Diseases
    • 6.1.5 Others
  • 6.2 Gene Therapy Products Market, By Product Type
    • 6.2.1 Gene Editing
    • 6.2.2 Gene Silencing
    • 6.2.3 Gene Transfer
    • 6.2.4 Gene Regulation
    • 6.2.5 Others
  • 6.3 Gene Therapy Products Market, By Ingredient Type
    • 6.3.1 Viral Vectors
    • 6.3.2 Non-viral Vectors
    • 6.3.3 Plasmid DNA
    • 6.3.4 Antisense Oligonucleotides
    • 6.3.5 Others
  • 6.4 Gene Therapy Products Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Research Institutes
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Gene Therapy Products Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Gene Therapy Products market is categorized based on

By Product Type

• Gene Editing
• Gene Silencing
• Gene Transfer
• Gene Regulation
• Others

By Application

• Oncology
• Genetic Disorders
• Neurological Disorders
• Cardiovascular Diseases
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Research Institutes
• Online Pharmacies
• Others

By Ingredient Type

• Viral Vectors
• Non-viral Vectors
• Plasmid DNA
• Antisense Oligonucleotides
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis
• Gilead Sciences
• Bluebird Bio
• Spark Therapeutics
• CRISPR Therapeutics
• Amgen
• Biogen
• Regeneron Pharmaceuticals
• AstraZeneca
• Roche
• AbbVie
• Sanofi
• Vertex Pharmaceuticals
• Intellia Therapeutics
• Catalent